Table 1.

Clinicopathological features compared between MF-CCA patients with SPARC tumor positive and stromal negative expression and other patients

	SPARC tumor positive and stromal negative expression (n=37)	Others (n=41)	P
Age (years)	59.98±11.33	59.54±12.68	0.872
Sex
Male	18 (54.5%)	15 (45.5%)	0.282
Female	19 (42.2%)	26 (57.8%)
Symptoms
Negative	8 (66.7%)	4 (33.3%)	0.147
Positive	29 (43.9%)	37 (56.1%)
AST (IU/L)
≦34	20 (51.3%)	19 (48.7%)	0.565
>34	17 (44.7%)	21 (55.3%)
ALT (U/L)
≦36	19 (47.5%)	21 (52.5%)	0.540
>36	17 (54.8%)	14 (45.2%)
ALP (U/L)
≦94	12 (52.2%)	11 (47.8%)	0.525
>94	23 (44.2%)	29 (55.8%)
Bilirubin (total) (mg/dL)
≦1.3	33 (51.6%)	31 (48.4%)	0.119
>1.3	4 (28.6%)	10 (71.4%)
Albumin (g/dL)
≦3.5	9 (40.9%)	13 (59.1%)	0.528
>3.5	24 (49.0%)	25 (51.0%)
Serum CEA (ng/mL)
≦5	9 (36.0%)	16 (64.0%)	0.160
>5	17 (54.8%)	14 (45.2%)
Stage
I	14 (37.8%)	11 (26.8%)	0.405
II	1 (2.7%)	5 (12.2%)
III	19 (51.4%)	21 (51.2%)
IV	3 (8.1%)	4 (9.8%)
Size (cm)
≦5	14 (43.8%)	18 (56.3%)	0.404
>5	23 (53.5%)	20 (46.5%)
Lymph node
Negative	22 (46.8%)	25 (53.2%)	0.901
Positive	14 (48.3%)	15 (51.7%)
Differentiated
Well	0 (00.0%)	2 (100.0%)	0.256
Moderate	19 (46.3%)	22 (53.7%)
Poorly	16 (48.5%)	17 (51.5%)
Others	2 (100.0%)	0 (00.0%)
Margin
Negative	27 (50.0%)	27 (50.0%)	0.496
Positive	10 (41.7%)	14 (58.3%)
Post-op chemotherapy
Without	12 (36.4%)	21 (63.6%)	0.094
With	25 (55.6%)	20 (44.4%)
Post-op radiotherapy
Without	34 (50.0%)	34 (50.0%)	0.317
With	3 (30.0%)	7 (70.0%)

Abbreviations: MF-CCA, mass-forming cholangiocarcinoma; SPARC, secreted protein acidic and rich in cysteine; AST, aspartate aminotransferase; IU, international unit; ALT, alanine aminotransferase; ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; op, operation.